LOVFF (Cannara Biotech) EBITDA Margin % : 22.49% (As of Nov. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cannara Biotech's EBITDA for the three months ended in Nov. 2024 was $4.04 Mil. Cannara Biotech's Revenue for the three months ended in Nov. 2024 was $17.94 Mil. Therefore, Cannara Biotech's EBITDA margin for the quarter that ended in Nov. 2024 was 22.49%.

Cannara Biotech EBITDA Margin % Historical Data

The historical data trend for Cannara Biotech's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech EBITDA Margin % Chart

Cannara Biotech Annual Data

Trend

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

EBITDA Margin %

Get a 7-Day Free Trial

-360.17

18.00

23.43

27.54

18.55

Cannara Biotech Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24
EBITDA Margin %	Get a 7-Day Free Trial															24.55	-4.65	25.35	25.36	22.49

Competitive Comparison of Cannara Biotech's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannara Biotech's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's EBITDA Margin % falls into.

Save Embed

;

Save Embed

;

Cannara Biotech EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Cannara Biotech's EBITDA Margin % for the fiscal year that ended in Aug. 2024 is calculated as

EBITDA Margin %	=	EBITDA (A: Aug. 2024 )	/	Revenue (A: Aug. 2024 )
	=	11.105	/	59.867
	=	18.55 %

Cannara Biotech's EBITDA Margin % for the quarter that ended in Nov. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Nov. 2024 )	/	Revenue (Q: Nov. 2024 )
	=	4.035	/	17.942
	=	22.49 %

Cannara Biotech (OTCPK:LOVFF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Cannara Biotech EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannara Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (OTCPK:LOVFF) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

8CB0:Germany LOVE:Canada

Address

1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3

Website

http://www.cannara.ca

Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .